MoineauWorld.com – Where Cooking Meets Tech & Everything Between

Tag: chronic rhinosinusitis without nasal polyps

Gateway Logistics: NASA Rethinks Resupply | Analysis by Brian Moineau

Posted on by Brian Moineau

At a crossroads: NASA rethinks Gateway logistics and what it means for lunar exploration

Imagine building a small, permanent outpost around the Moon and then pausing to ask whether the delivery trucks you planned for it are still the best option. That’s essentially where NASA finds itself with the Gateway logistics program — paused, reassessing and weighing a traditional plan against newer commercial paths that could reshape how we supply cislunar operations.

This is not a simple procurement debate about parts and prices. It’s a decision that touches politics, industrial partners, launch architecture, and the cadence of Artemis missions. Here’s a friendly, clear look at what’s happening, why it matters, and one perspective on where this could lead.

Quick summary

  • NASA is reassessing logistics for the lunar Gateway and is “at a crossroads” between previously chosen approaches and alternative commercial concepts.
  • The agency originally selected SpaceX’s Dragon XL for Gateway cargo but has studied alternative proposals — including the potential use of Starship — and paused formal contract progression while policy and program reviews play out.
  • The outcome will affect the Artemis cadence, international partners, industrial contractors, and the emerging commercial cislunar market.

Why logistics matter more than they sound

Logistics sound boring until you’re stranded without oxygen filters, power cells, or experiment hardware 250,000 miles from home. The Gateway is intended to be a reusable lunar-orbit outpost supporting crews, science and surface missions. Supplying it reliably is the backbone of the whole architecture:

  • Resupply frequency and mass capacity determine how long crews can stay and what experiments they can run.
  • Vehicle design affects whether the Gateway gains temporary habitable volume (by docking cargo ships) or relies on internal spares only.
  • Disposal capability (removing waste, returning hardware) matters for station sustainability.
  • Costs and launch cadence influence whether Artemis becomes episodic or a sustainable program that can scale.

So when NASA reopens its logistics plan, the consequences ripple through mission design, contractor roles, and international commitments.

What changed and what NASA is weighing

The Gateway Logistics Services program originally followed a model similar to ISS resupply: NASA selected a dedicated cargo provider (SpaceX was chosen in 2020 to use a Dragon XL variant). But development and program timelines shifted, and broader Artemis reviews — plus a temporary budgetary wobble in 2025–2026 — put Gateway logistics into review.

Key points from the recent reporting and agency actions:

  • NASA paused formalizing the full logistics contract work and has been conducting internal reviews of Artemis program timing, budgets and priorities. (This included delays around authorization to proceed with SpaceX’s awarded contract.) (spacenews.com)
  • Agency officials said they evaluated an alternative proposal from SpaceX and studied whether Starship could serve Gateway logistics instead of Dragon XL, to better align with how Starship is being developed commercially. That assessment left NASA “at a crossroads.” (spacelaunchschedule.com)
  • Political and budget actions complicated timing: a proposed FY2026 budget sought to cancel Gateway, but Congressional funding restored program support — leaving NASA to re-evaluate timing and architecture under shifting guidance. (spacenews.com)

Those moves don’t mean NASA is abandoning Gateway. The agency continues to make progress on major Gateway hardware — for example, the HALO habitation and logistics outpost recently moved through integration steps toward launch — but logistics decisions will shape how that hardware is used operationally once in orbit. (nasa.gov)

The two contrasting architectures

  • Dragon XL (original plan)

    • Pros: Based on an established, flight-proven Dragon heritage; lower development risk relative to an entirely new vehicle variant; defined performance envelope for pressurized and unpressurized cargo.
    • Cons: Lower mass-per-flight compared with what Starship promises; cadence and cost depend on Falcon Heavy and Dragon variant availability and NASA procurement timelines. (spacenews.com)

  • Starship (commercial alternative under study)

    • Pros: Extremely high payload capacity and potential for rapid reusability that could lower cost per kg and increase delivery cadence; could support large cargo movements and even surface logistics if operational.
    • Cons: Less flight-proven (especially in cislunar operations at the time of evaluation); would represent a bigger architectural shift for Gateway interfaces, docking and operations; raises industrial and international partner implications. (filmogaz.com)

NASA’s choice isn’t just technical — it’s strategic. Opting for Starship-like capability could accelerate supply mass and lower long-term costs, but introducing such a different architecture midstream raises integration, partner, and policy questions.

What this means for industrial partners and international contributors

Gateway is an international program. Europe, Canada, Japan and partners have committed hardware, systems and funding that assume certain timelines and an operational model. A logistics architecture change affects:

  • Manufacturers building Gateway modules and payloads (schedule and interface requirements).
  • Companies that had planned to bid or provide services under the original RFP model.
  • Congressional and diplomatic commitments tied to program timelines and cost expectations.

If NASA pivots to a newer commercial model, contracts, international agreements and supply chains will need rework — and that creates industrial winners and losers depending on how work is reallocated.

The policy and budget angle

Part of the pause reflects a bigger picture: an internal Artemis program review tied to budget proposals and shifting policy priorities. The timing of final guidance — reportedly expected following key mission milestones like Artemis 2 — will matter a lot. Until NASA has a clear policy and consistent budget line, big procurement starts can remain on hold. (spacenews.com)

My take

This reassessment is healthy. Programs that lock large, multi-year contracts without checking whether massively cheaper or higher-capacity commercial services will soon exist risk wasting money or hobbling future capability. SpaceX’s Starship promises a different scale of delivery, and it’s sensible for NASA to study whether that commercial trajectory can better meet Gateway’s long-term needs.

But patience matters: partners and suppliers need clarity. NASA should aim for a decision window that balances prudence with transparency — setting firm dates for architecture selection, clear contingency plans for international partners, and contractual roadmaps that protect taxpayers while enabling innovation.

If NASA gets this right, Gateway logistics could pivot from an expensive, bespoke habit of the past to a flexible, commercial-enabled backbone for sustained lunar presence.

The SEO-friendly essentials (what to remember)

  • Primary keywords: Gateway logistics, NASA Gateway, Dragon XL, Starship, Artemis, cislunar logistics.
  • Short phrase to repeat mentally: logistics decide capability — the way we deliver to the Moon will shape how long and how often we stay.

Final thoughts

We’re watching a classic transition moment: government-led architecture meets rapidly evolving commercial capability. NASA’s decision on Gateway logistics could set the tone for decades of lunar operations — making the agency’s careful, if sometimes slow, reassessment a potentially wise move. The ideal outcome is a hybrid path that preserves international commitments, minimizes risk for near-term missions, and leaves the door open to scale with commercial advances.

Sources

(Note: SpaceNews is the originating reporting outlet on recent program assessments; NASA provides hardware and program status updates. The story combines these perspectives to look beyond the headlines toward programmatic and strategic impact.)

Insmed pivots after brensocatib setback | Analysis by Brian Moineau

Posted on by Brian Moineau

A surprising pivot from Insmed: what the BiRCh results mean for brensocatib and the company’s strategy

The biotech world loves dramatic arcs: a promising molecule rises, investors cheer, and then — sometimes — the plot takes an unexpected turn. On December 17, 2025, Insmed released topline results from the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP). The verdict was blunt: the study did not meet its primary or secondary efficacy endpoints. Insmed immediately discontinued the CRSsNP program, while also announcing the acquisition of a Phase 2-ready monoclonal antibody, INS1148, to bolster its respiratory and inflammatory pipeline.

Let’s unpack what happened, why it matters, and where Insmed might reasonably go from here.

Quick summary of the news

  • Date of announcement: December 17, 2025.
  • Study: Phase 2b BiRCh — brensocatib versus placebo in CRSsNP, 24 weeks, ~288 patients across 104 sites.
  • Result: Neither the 10 mg nor 40 mg dose met the primary endpoint (change in sinus Total Symptom Score) or secondary endpoints.
  • Safety: No new safety signals; tolerability consistent with prior studies, including in the higher 40 mg arm.
  • Immediate corporate action: Insmed discontinued the CRSsNP development program for brensocatib.
  • Simultaneous strategic move: Acquisition of INS1148 (OpSCF), a monoclonal antibody intended for interstitial lung disease and moderate-to-severe asthma; Insmed plans Phase 2 development.

Why the BiRCh failure matters

  • Brensocatib had momentum. The drug showed promising results in non-cystic fibrosis bronchiectasis (NCFB) and had become a central part of Insmed’s growth story. Expectations built around expanding brensocatib into other inflammatory and respiratory indications.
  • CRSsNP is biologically complex with no reliable animal models. Insmed described the BiRCh trial as a proof-of-concept aimed at testing whether brensocatib’s DPP1 inhibition could translate into symptom relief. The neutral result gives a clear — if disappointing — answer.
  • Financial and R&D implications. Discontinuing a development program reduces near-term R&D spend on that indication, but it also cuts potential long-term upside if CRSsNP had proven a meaningful market. The market reaction (sharp stock drop reported in related coverage) reflects lost optionality and investor re-pricing of future revenue scenarios.
  • Scientific signal. The lack of efficacy despite adequate dosing (including the company’s highest dose tested) raises mechanistic questions about neutrophil serine protease inhibition in CRSsNP specifically. It also tempers optimism for other indications where the drug’s mechanism is less directly validated.

What the data showed (topline numbers)

  • Primary endpoint (28-day average of daily sTSS at Week 24):
    • Placebo LS mean: -2.44
    • Brensocatib 10 mg LS mean: -2.21
    • Brensocatib 40 mg LS mean: -2.33
  • Safety: Treatment-emergent adverse events were similar between arms; no new safety concerns, and serious adverse event rates were low and comparable.

Those numbers show minimal separation from placebo on symptom improvement — the clinical signal simply wasn’t there.

The strategic pivot: INS1148 acquisition

  • What Insmed bought: INS1148 is a monoclonal antibody (formerly OpSCF) that targets a specific isoform of Stem Cell Factor (SCF248). The proposed advantage is to block the inflammatory cascade downstream of c-Kit signaling while sparing homeostatic/tissue-healing pathways.
  • Initial focus: Insmed plans Phase 2 programs in interstitial lung disease and moderate-to-severe asthma. This aligns with the company’s pulmonary focus and offers a new, complementary modality (mAb vs small-molecule DPP1 inhibitor).
  • Why this matters: Acquiring a clinical-stage asset diversifies Insmed’s pipeline at a time when brensocatib’s expansion into CRSsNP is off the table. It signals the company is doubling down on respiratory/inflammatory areas while mitigating the impact of the BiRCh result.

The investor dilemma

  • Near-term pain: Market volatility is expected after a late-2025 negative readout on an eagerly watched indication. Analysts and short-term traders will re-evaluate revenue forecasts and valuation multiples.
  • Longer-term perspective: Insmed still has commercial momentum from brensocatib in bronchiectasis (marketed as Brinsupri in some territories), other ongoing studies (e.g., hidradenitis suppurativa CEDAR study), and now INS1148 to potentially broaden indications. For investors with a multi-year horizon, the company’s runway and portfolio execution matter more than a single failed indication.
  • Risk-reward recalibration: The failure reduces optionality and likely moderates peak-sales estimates for brensocatib overall. But the absence of new safety signals and the company’s ability to redeploy capital toward a novel mAb program may keep upside for those who believe in Insmed’s broader strategy.

What this means for brensocatib’s other programs

  • Hidradenitis suppurativa (HS) and other non-pulmonary indications may be scrutinized more closely. A lack of efficacy in CRSsNP doesn’t doom those programs, but it raises caution and increases the value of positive, indication-specific data.
  • For bronchiectasis, prior strong late-stage results remain intact. Regulatory and commercial timelines for that indication are independent of the CRSsNP result, but market expectations may be tempered.

Takeaways for clinicians, patients, and industry watchers

  • Clinicians and patients with CRSsNP: The BiRCh data suggest brensocatib will not become an option for CRSsNP. Patients should continue following evidence-based care and consult their physicians for approved therapies and management strategies.
  • Industry watchers: This is a reminder that translating mechanism-based therapies into symptom relief in human disease is hard, especially in diseases lacking translational animal models. Creative acquisitions (like INS1148) are a common industry response to maintain pipeline momentum.

My take

Insmed’s BiRCh outcome is a textbook example of how clinical development reorders expectations. The result is disappointing, but not catastrophic: the company still has a commercially relevant product in bronchiectasis and a pipeline it can re-shape. Acquiring INS1148 is a pragmatic move — it signals an appetite to diversify modality risk and lean into respiratory immunology with a different mechanism.

Failures like this sting publicly because they are visible and immediate. But they can also sharpen corporate focus. If Insmed executes well on ongoing brensocatib programs and advances INS1148 thoughtfully into Phase 2, the company can emerge with a clearer, perhaps stronger strategic identity — albeit one that looks different than the path investors may have anticipated at the start of 2025.

Further reading

  • Insmed press release: “Insmed Provides Clinical and Business Update” (December 17, 2025) — for the full topline text and company commentary.
  • Reuters and other industry coverage — for market reaction and context around brensocatib’s prior successes in bronchiectasis.

Sources



Related update: We recently published an article that expands on this topic: read the latest post.